Skip to content

Medication Reconciliation for Patients Over 65 Years Old : Cost Analysis of the Process Implemented in the Polyvalent Internal Medical Unit of Rennes University Hospital

Medication Reconciliation for Patients Over 65 Years Old : Cost Analysis of the Process Implemented in the Polyvalent Internal Medical Unit of Rennes University Hospital

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03670433
Acronym
CONTEMPS
Enrollment
100
Registered
2018-09-13
Start date
2017-09-05
Completion date
2017-10-31
Last updated
2018-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Reconciliation

Keywords

Medication reconciliation, Care path, Prevention

Brief summary

Among the strategies to secure the patient's care path, medication reconciliation is a powerful approach for the prevention and interception of medication errors.

Detailed description

All medication errors are not serious. Nevertheless 4 studies show that respectively 5.6%, 5.7%, 6.3% and 11.7% of the medication errors intercepted by medication reconciliation (MR) could have had major, critical or catastrophic consequences for patients. If the consequences of a medication error have a clinical or institutional translation for the patient, they can also directly impact the hospital or caregivers, for example by extending the average length of stay or by increasing the number of consultations or readmissions. The efficiency of the medication reconciliation approach has never been evaluated in France in comparison with standard care. Before initiating cost-effectiveness studies, we propose to conduct a micro-costing study to evaluate the production costs of this conciliation approach. The costs are almost exclusively related to human resources and the present study will assess the time spent by the different actors involved in the process.

Interventions

OTHERCost analysis of medication reconciliation

1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS). 2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS.

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 65 years old * Patient non-institutionalized at entry * For MR : * Entry : patients admitted at UMIP between 09/04/2017 and 10/31/2017 * Discharge : patients returning home or going to a rehabilitation service between 04/09/2017 and 31/10/2017 and having received MR evaluation

Exclusion criteria

* Patients not returning home * Refusal of participation * Major persons subject to legal protection (safeguard of justice, guardianship), persons deprived of their liberty

Design outcomes

Primary

MeasureTime frameDescription
Time spent by professionalsAt the inclusion dayEvaluation of the time spent by each professionals involved in the completion of each step of the MR process.
Average cost of MR processAt the inclusion dayEvaluation of average cost of MR process at UMIP. Only costs related to human resources are considered.
Number of unintentional discrepancies detectedAt the inclusion dayNumber of unintentional discrepancies detected during MR at admission of patients at UMIP.
Severity of unintentional discrepancies detectedAt the inclusion daySeverity of unintentional discrepancies detected during MR at admission of patients at UMIP. Evaluation based on the algorithm provided by the HAS.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026